Contribution of families using the GenIDA database to the description of MED13L syndrome and literature review
- PMID: 40389839
- PMCID: PMC12087057
- DOI: 10.1186/s11689-025-09618-4
Contribution of families using the GenIDA database to the description of MED13L syndrome and literature review
Abstract
The GenIDA project aims to improve the understanding and management of rare genetic forms of intellectual disability by fostering collaboration among patients, caregivers, healthcare professionals, and research professionals. Clinical data is provided by patients' families via a structured questionnaire to identify medically relevant insights and better understand the natural history of rare diseases. This study focused on MED13L syndrome, analyzing data from 41 patients in the GenIDA database and comparing it with 102 cases from the scientific literature and 6 new descriptions of patients from our medical center.The GenIDA series confirmed the key features of MED13L syndrome, including global developmental delay, poor speech, intellectual disability, and cardiac defects (OMIM #616789), at frequencies similar to those reported in the literature. The GenIDA series identified a higher prevalence of visual impairment (76%) and highlighted under-recognized musculoskeletal issues, such as foot deformities, which had previously received little attention. This study highlights the value of family-reported data in describing the full phenotype of rare syndromes. A comprehensive review of published cases showed that patients with missense variants have more severe impairments, including increased cardiac defects, global developmental delay, and a higher incidence of epilepsy, than patients with premature truncated variants.These findings highlight the importance of family involvement in rare disease research and the need for further studies to explore genotype-phenotype correlations to improve patient care and outcomes.
Keywords: Family; Intellectual disability; MED13L; Patient registry.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: Clinical details were collected and informed consent was obtained for genetic studies. Analyses were performed on a diagnostic basis in accordance with the bioethical rules of French law. Competing interests: The authors declare no competing interests.
Similar articles
-
Is MED13L-related intellectual disability a recognizable syndrome?Eur J Med Genet. 2019 Feb;62(2):129-136. doi: 10.1016/j.ejmg.2018.06.014. Epub 2018 Jun 27. Eur J Med Genet. 2019. PMID: 29959045
-
MED13L-related intellectual disability: involvement of missense variants and delineation of the phenotype.Neurogenetics. 2018 May;19(2):93-103. doi: 10.1007/s10048-018-0541-0. Epub 2018 Mar 6. Neurogenetics. 2018. PMID: 29511999
-
Genotype-phenotype evaluation of MED13L defects in the light of a novel truncating and a recurrent missense mutation.Eur J Med Genet. 2017 Sep;60(9):451-464. doi: 10.1016/j.ejmg.2017.06.004. Epub 2017 Jun 21. Eur J Med Genet. 2017. PMID: 28645799
-
Report of a de novo c.2605C > T (p.Pro869Ser) change in the MED13L gene and review of the literature for MED13L-related intellectual disability.Ital J Pediatr. 2020 Jul 9;46(1):95. doi: 10.1186/s13052-020-00847-y. Ital J Pediatr. 2020. PMID: 32646507 Free PMC article. Review.
-
Two novel pathogenic variants in MED13L: one familial and one isolated case.J Intellect Disabil Res. 2021 Dec;65(12):1049-1057. doi: 10.1111/jir.12891. Epub 2021 Oct 28. J Intellect Disabil Res. 2021. PMID: 34713510 Review.
References
-
- Smol T, Petit F, Piton A, Keren B, Sanlaville D, Afenjar A, et al. MED13L-related intellectual disability: involvement of missense variants and delineation of the phenotype. Neurogenetics. 2018;19(2):93–103. - PubMed
-
- Tørring PM, Larsen MJ, Brasch-Andersen C, Krogh LN, Kibæk M, Laulund L, et al. Is MED13L-related intellectual disability a recognizable syndrome? Eur J Med Genet. 2019;62(2):129–36. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical